December 4, 2020
Skylar Jeremias
To spur more biosimilar development and reduce anticompetitive practices, the company argued the FDA could improve its interpretation of the term “strength” in the Biologics Price Competition and Innovation Act (BPCIA).
November 30, 2020
In November, the Supreme Court heard arguments on the Affordable Care Act, Europe fired up its efforts to create a more biosimilar-friendly environment, and Genentech fought to protect its bevacizumab franchise.
November 27, 2020
Tony Hagen
The European Commission (EC) said it will take the lessons learned from the coronavirus disease 2019 (COVID-19) pandemic and build a better marketplace for generics and biosimilars.
November 21, 2020
Bincy P. Abraham, MD
Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.
November 19, 2020
Prior to the turmoil of the pandemic, the FDA and CMS were at work on shoring up the biosimilars market, and this work continues on various fronts, a regulatory/policy expert explains.
November 17, 2020
Despite a rocky power transition at the federal level, the compass heading for biosimilars is unchanged, said policy expert Molly Burich.
November 14, 2020
In Europe, the pandemic has revealed problems within health care systems and the need to increase access to biosimilars and reform health care policies.
November 5, 2020
Medicines for Europe, a generic and biosimilar trade association, contends in a white paper that legal and regulatory loopholes increasingly keep competing drugs off the market.
November 2, 2020
Deana Ferreri, PhD
This study of specialty drug spending looks beyond rebates to evaluate growth in spending from 2010 to 2017.
October 29, 2020
The American College of Rheumatology (ACR) has joined with other provider groups in opposing a UnitedHealthcare (UHC) plan that could increase patient out-of-pocket costs.
